Capital Asset Advisory Services’s Pfizer PFE Stock Holding History

Capital Asset Advisory Services’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.19M	Buy	115,839 +4,889	+4%	+$130K	0.12%	95
2025 Q4	$2.82M	Buy	110,950 +1,520	+1%	+$38.3K	0.11%	101
2025 Q3	$2.79M	Buy	109,430 +37,402	+52%	+$923K	0.12%	100
2025 Q2	$1.8M	Buy	72,028 +14	+0%	+$326	0.08%	112
2025 Q1	$1.78M	Sell	72,014 -22,298	-24%	-$583K	0.09%	111
2024 Q4	$2.51M	Buy	94,312 +5,632	+6%	+$153K	0.12%	105
2024 Q3	$2.59M	Sell	88,680 -1,037	-1%	-$30.3K	0.13%	100
2024 Q2	$2.49M	Buy	89,717 +2,572	+3%	+$70.8K	0.13%	98
2024 Q1	$2.32M	Buy	87,145 +14,492	+20%	+$402K	0.13%	99
2023 Q4	$2.09M	Buy	72,653 +8,166	+13%	+$247K	0.13%	100
2023 Q3	$2.14M	Buy	64,487 +7,361	+13%	+$260K	0.15%	83
2023 Q2	$2.07M	Buy	57,126 +1,874	+3%	+$72.9K	0.14%	81
2023 Q1	$2.25M	Buy	55,252 +3,015	+6%	+$130K	0.17%	70
2022 Q4	$2.72M	Buy	52,237 +5,209	+11%	+$250K	0.22%	55
2022 Q3	$2.06M	Buy	47,028 +1,530	+3%	+$74.3K	0.27%	48
2022 Q2	$2.38M	Sell	45,498 -3,732	-8%	-$190K	0.26%	56
2022 Q1	$2.55M	Sell	49,230 -1,730	-3%	-$89.8K	0.27%	53
2021 Q4	$3.01M	Buy	50,960 +2,406	+5%	+$119K	0.32%	44
2021 Q3	$2.09M	Sell	48,554 -1,896	-4%	-$84K	0.23%	62
2021 Q2	$1.98M	Buy	50,450 +3,827	+8%	+$149K	0.22%	66
2021 Q1	$1.69M	Buy	46,623 +460	+1%	+$16.3K	0.25%	65
2020 Q4	$1.7M	Buy	46,163 +4,223	+10%	+$155K	0.3%	56
2020 Q3	$1.46M	Sell	41,940 -13,063	-24%	-$458K	0.31%	61
2020 Q2	$1.99M	Buy	55,003 +4,250	+8%	+$144K	0.43%	41
2020 Q1	$1.8M	Buy	50,753 +8,417	+20%	+$287K	0.48%	43
2019 Q4	$1.54M	Buy	42,336 +18,490	+78%	+$659K	0.36%	51
2019 Q3	$813K	Buy	23,846 +1,587	+7%	+$57.7K	0.54%	34
2019 Q2	$915K	Buy	22,259 +799	+4%	+$31.7K	0.7%	32
2019 Q1	$865K	Sell	21,460 -833	-4%	-$33.4K	1.12%	15
2018 Q4	$923K	Hold	22,293	–	–	0.88%	27
2018 Q3	$932K	Hold	22,293	–	–	0.79%	30
2018 Q2	$767K	Buy	22,293 +211	+1%	+$7.21K	0.69%	34
2018 Q1	$744K	Hold	22,082	–	–	0.69%	38
2017 Q4	$759K	Hold	22,082	–	–	0.69%	35
2017 Q3	$748K	Hold	22,082	–	–	0.68%	35
2017 Q2	$705K	Sell	22,082 -239	-1%	-$7.54K	0.45%	53
2017 Q1	$724K	Buy	22,321 +581	+3%	+$18.3K	0.52%	43
2016 Q4	$670K	Sell	21,740 -1,054	-5%	-$32.2K	0.57%	41
2016 Q3	$732K	Buy	22,794 +387	+2%	+$12.9K	0.97%	20
2016 Q2	$749K	Buy	22,407 +105	+0.5%	+$3.35K	0.99%	22
2016 Q1	$627K	Buy	22,302 +791	+4%	+$22.6K	0.68%	35
2015 Q4	$659K	Buy	+21,511	New	+$677K	0.92%	25

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Capital Asset Advisory Services's PFE Position: Q1 2026 in Review

Capital Asset Advisory Services increased its Pfizer (PFE) stake by 4.4% in Q1 2026, buying an estimated $130K and bringing the position to 115,839 shares worth $3.19M. The position accounts for 0.12% of the portfolio, ranked #95.

Capital Asset Advisory Services first reported a position in PFE in Q4 2015 and has held it in 42 quarters since. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

Capital Asset Advisory Services held 115,839 shares of Pfizer worth $3.19M as of Q1 2026.
Capital Asset Advisory Services bought 4,889 Pfizer shares in Q1 2026, an estimated $130K.
Pfizer made up 0.12% of Capital Asset Advisory Services's portfolio in Q1 2026, its #95 holding.
Capital Asset Advisory Services first reported a position in Pfizer in Q4 2015 and has held it in 42 quarters since.
2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.